Skip navigation

DSpace

機構典藏 DSpace 系統致力於保存各式數位資料(如:文字、圖片、PDF)並使其易於取用。

點此認識 DSpace
DSpace logo
English
中文
  • 瀏覽論文
    • 校院系所
    • 出版年
    • 作者
    • 標題
    • 關鍵字
  • 搜尋 TDR
  • 授權 Q&A
    • 我的頁面
    • 接受 E-mail 通知
    • 編輯個人資料
  1. NTU Theses and Dissertations Repository
  2. 醫學院
  3. 分子醫學研究所
請用此 Handle URI 來引用此文件: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27483
完整後設資料紀錄
DC 欄位值語言
dc.contributor.advisor蘇怡寧
dc.contributor.authorChien-Hui Changen
dc.contributor.author張千慧zh_TW
dc.date.accessioned2021-06-12T18:06:43Z-
dc.date.available2009-02-19
dc.date.copyright2008-02-19
dc.date.issued2007
dc.date.submitted2007-12-28
dc.identifier.citation1. Marfan AB. (1896). Un cas de deformation congenitale des quatre membres, plus
prononce aux extremetes, characterise par l’allongement des os avec un certain
degre d’amincissement. Bull Mem Soc Med Hop (Paris) 13:220–6.
2. Salle V. (1912). Ueber einen fall von angeborner abnormen Grosse der Extremitaten mit einen an Akronemegalia erinerden Symptomenkomplex. Jahrb Kinderkeilk 75:540–50.
3. Pyeritz RE. (2000) The Marfan syndrome. Annu Rev Med 51:481–510.
4. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, PuVenberger EG, Hamosh A, Nanthakumar EJ, Curristin SM, Stetten G, Meyers DA, Francomano CA (1991) Marfan syndrome caused by a recurrent de novo missense mutation in the Wbrillin gene. Nature 352:337–339.
5. Dietz HC, Pyeritz RE, Hall BD, et al (1991) The Marfan syndrome locus: confirmation of assignment to chromosome 15 and identification of tightly linked markers at 15q15-q21.3. Genomics 9:355—61.
6. Weyman AE, Scherrer-Crosbie M (2004) Marfan syndrome and mitral valve prolapse. J Clin Invest 114:1543—6.
7. Lee B, Godfrey M, Vitale E, et al (1991) Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genes. Nature 352:330-4.
8. Mizuguchi T, Collod-Beroud G, Akiyama T, et al (2004) Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 36:855-60.
9. Kaartinen, V. and D. Warburton (2003) Fibrillin controls TGF-β activation. Nat Genet 33(3): 331-2.
10. Halliday DJ, Hutchinson S, Lonie L, Hurst JA, Firth H, Handford PA, Wordsworth P (2002) Twelve novel FBN1 mutations in Marfan syndrome and Marfan related phenotypes test the feasibility of FBN1 mutation testing in clinic practice. J Med Genet 39:589-93.
11. Korkko J, Kaitila I, Lonnqvist L, Peltonen L, Ala-Kokko L (2002) Sensitive of conformation sensitive gel electrophoresis in detecting mutations in Marfan syndrome and related conditions. J Med Genet 39:34-41.
12. Loeys B, De Backer J, Van Acker P, Wettinck K, Pals G, Nuytinck L, Coucke P, De Paepe A (2004) Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome. Hum Mutat 24:140-6.
13. Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, Meyers J, Leitch CC, Katsanis N, Sharifi N, Xu FL, Myers LA, Spevak PJ, Cameron DE, De Backer J, Hellemans J, Chen Y, Davis EC, Webb CL, Kress W, Coucke P, Rifkin DB, De Paepe AM, Dietz HC (2005) A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutation in TGFBR1 or TGFBR2. Nat Genet 37:275-81 .
14. DePaepe A, Deitz HC, Devereux RB, Hennekem R, Pyeritz RE. (1996) Revised diagnostic criteria for the Marfan syndrome. Am. J. Med. Genet. 62:417–26.
15. Mátyás G, De Paepe A, Halliday A, Boileau C, Pals G, Steinmannl B (2002) Evaluation and Application of Denaturing HPLC for Mutation Detection in Marfan Syndrome: Identification of 20 Novel Mutations and Two Novel Polymorphisms in the FBN1 Gene. Hum Mutat 19:443-456.
16. Arbustini E et al (2005) Identification of Sixty-two Novel and Twelve Known FBN1 Mutations in Eighty-one Unrelated Probands With Marfan Syndrome and Other Fibrillinopathies. Hum Mutat 26(5):494-509
17. Huber CG, Oefner PJ, Bonn GK (1993) High-resolution liquid chromatography of oligonucleotides on nonporous alkylated styrene-divinylbenzene copolymers. Anal Biochem 212:351-8.
18. O’Donovan MC, Oefner PJ, Roberts SC, Austin J, Hoogendoorn B, Guy C, Speight G, Upadhyaya M, Sommer SS, McGuffin P (1998) Blind analysis of denaturing high-performance liquid chromatogramphy as a tool for mutation detection. Genomics 52:44-9.
19. Jones AC, Austin J, Hansen N, Hoogendoorn B, Oefner PJ, Cheadle JP, O’Donovan MC (1999) Optimal temperature selection for mutation detection by denaturing HPLC and comparison to single-stranded conformation polymorphism and heteroduplex analysis. Clin Chem 45:1133-40.
20. Jesse Montgomery, Carl T Wittwer, Robert Palais & Luming Zhou (2007) Simultaneous mutation scanning and genotyping by high-resolution DNA melting analysis Nature 2(1):59-66
21. Michael Liew, Robert Pryor, Robert Palais, Cindy Meadows, Maria Erali, Elaine Lyon, and Carl Wittwer (2004) Genotyping of Single-Nucleotide Polymorphisms by High-Resolution Melting of Small Amplicons. Clin Chem 50(7):1156-1164
22. Luming Zhou, Lesi Wang, Robert Palais, Robert Pryor, and Carl T. Wittwer (2005) High-Resolution DNA Melting Analysis for Simultaneous Mutation Scanning and Genotyping in Solution. Clin Chem 51(10):1770-1777
23. Mark G. He rrmann, Jacob D. Durtschi, L. Kathryn Bromley, Carl T. Wittwer, and Karl V. Voelkerding (2006) Amplicon DNA Melting Analysis for Mutation Scanning and Genotyping: Cross-Platform Comparison of Lnstruments and Dyes. Clin Chem 52(3):494-503
24. Lan-Szu Chou, Elaine Lyon, and Carl T. Wittwer (2005) A Comparison of High-Resolution Melting Analysis With Denaturing High-Performance Liquid Chromatography for Mutation Scanning. Am J Clin Pathol 124:330-338
25. Alan Graham Stuart, Andrew Williams (2007) Marfan’s syndrome and the heart. Arch Dis Child 92:351-356.
26. Choy YS, Dabora SL, Hall F et al (1999) Superiority of denaturing high performance liquid chromatography over single-stranded conformation and conformation-sensitive gel electrophoresis for mutation detection in TSC2. Ann Hum Genet 63(Pt5): 383-391.
27. Buyse IM, Fang P, Hoon KT, Amir RE, Zoghbi HY, Roa BB (2000) Diagnostic testing for Rett syndrome by DHPLC and direct sequencing analysis of the MECP2 gene: identification of several novel mutations polymorphisms. Am J Hum Genet 67: 1428-1436.
28. Koenigsberg M, Factor S, Cho S, et al. (1981) Fetal Marfan syndrome: prenatal ultrasound diagnosis with pathological confirmation of skeletal and aortic lesions. Prenat Diagn 1:241–7.
29. Lipscomb KJ, Clayton-Smith J, Harris R. (1997) Evolving phenotype of Marfan’s syndrome. Arch Dis Child 76:41–6.
30. Peter N.R. (2002) Mutations of FBN1 and Genotype–Phenotype Correlations in Marfan Syndrome and Related Fibrillinopathies. Hum Mutat 20(3): 153-61
31. Booms, P., J. Cisler, et al. (1999). Novel exon skipping mutation in the fibrillin-1 gene: two 'hot spots' for the neonatal Marfan syndrome. Clin Genet 55(2):110-7.
32. Putnam EA, Cho M, Zinn AB, Towbin JA, Byers PH, Milewicz DM. (1996) Delineation of the Marfan phenotype associated with mutations in exons 23-32 of the FBN1 gene. Am J Med Genet 62: 233-242.
33. Hennekam RC. (2005) Severe infantile Marfan syndrome versus neonatal Marfan syndrome. Am J Med Genet A 139:1.
34. Tiecke, F., S. Katzke, et al. (2001). Classic, atypically severe and neonatal Marfan syndrome: twelve mutations and genotype-phenotype correlations in FBN1 exons 24-40. Eur J Hum Genet 9(1):13-21.
dc.identifier.urihttp://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27483-
dc.description.abstract馬凡氏症是一種自體顯性遺傳疾病,是由於連接組織出問題所導致,其中主要可分為三大類:骨骼,眼睛,以及心臟血液系統等。依國外統計數據,其發生率約每五千人就會有一人是馬凡氏症的患者(1/5,000 ~ 1/20,000),目前已知大多數的患者是由於FBN1基因(Fibrillin gene)突變所導致,此基因位於染色體15q21.1的位子,於1991年被定位出來;而少數的患者則是由於TGFBR2基因(Transforming growth factor-β 2 receptor gene)突變所導致,此基因是於2004年才被定位出來的,位於染色體3p24.1的位子,命名為馬凡氏症第二型基因。
本論文所提出的方法是利用聚合酶連鎖反應(PCR)加上DNA片段突變分析儀(DHPLC)來建立快速且可信的台灣人馬凡氏症的檢測平台同時建立台灣人的馬凡氏症突變點位(mutation site)和多型性點位(polymorphism site)的資料庫。在此研究中,將DNA的來源分成兩部分,一部分是有家族史的個案,共有22個家族,另一部分是偶發性的個案,共有43個個案;結果顯示,若DNA片段突變分析儀(DHPLC)有偵測到的個案,再使用定序(Sequence)方法確認,皆可得到同樣的結果;對於點突變的檢測而言,有家族史的檢測率是77.3%,沒有家族史的檢測率是32.6%。
相較於傳統的基因突變檢測方法,例如:Single Strand Conformation polymorphism(SSCP)或是直接定序(Sequence),在此篇論文當中所提及到的結合聚合酶連鎖反應(PCR)加上DNA片段突變分析儀(DHPLC)不僅可提供一種高效率、高準確率、高可信度、又可節省金費的技術平台,並可同時建立台灣人馬凡氏症的基因資料庫,由於此基因相當大,共有65 exons,若有資料庫可供人參考,便可將所節省的時間用於其他更需要的地方。
zh_TW
dc.description.abstractMarfan syndrome (MFS) is an autosomal dominant disorder of connective tissue, and its cardinal manifestations involve the skeletal, ocular, and cardiovascular systems. According to the statistical series, its prevalence is between 1/5,000 ~ 1/20,000. We now know that MFS was caused by mutations of FBN1 (Fibrillin gene) at 15q21.1 was reported in 1991. Less frequently, MFS was caused by mutations of TGFBR2 (Transforming growth factor-β 2 receptor gene)at 3p24.1 was reported in 2004. This is named Marfan syndrome type II.
In the thesis, we established a rapid and reliable detection system of genetic diagnosis and we constructed database including mutation site and polymorphism site for the Taiwanese patient with Marfan syndrome by using PCR/DHPLC assay. In this study, we decided the original DNA into two groups; one group had family history, including 22 families, and the other group did not have family history, including 43 cases. The result revealed that the data of DHPLC who compatible with the data of sequence, and the mutation detection rate of the cases with family history was 77.3%, and the mutation detection rate of the cases without family history was 32.6%.
Comparing with the traditional technology of genetic diagnosis, for example, single strand conformation polymorphism(SSCP)or direct sequence, we demonstrated that the PCR/DHPLC assay was not only an efficient, accurate, reliable, and saving-money technique for the gene diagnosis but also set up the Taiwanese database of the Marfan syndrome to help people who work for the gene testing of FBN1 to saving money and valuable time .
en
dc.description.provenanceMade available in DSpace on 2021-06-12T18:06:43Z (GMT). No. of bitstreams: 1
ntu-96-P94448011-1.pdf: 1112728 bytes, checksum: c4b360b5fdff982bd2b86ca94195a6e2 (MD5)
Previous issue date: 2007
en
dc.description.tableofcontents圖目錄-----------------------------------------------------------------VIII
表目錄------------------------------------------------------------------IX
中文摘要----------------------------------------------------------------X
英文摘要----------------------------------------------------------------XI
一、緒論------------------------------------------------------------------1
1-1 『馬凡氏症』的由來----------------------------------------------------------1
1-2 馬凡氏症之簡介-------------------------------------------------------------1
1-2-1 馬凡氏症之相關基因----------------------------------------------1
1-2-2 FBN1基因和TGFBR2基因之間相互關係--------------------2
1-2-3 FBN1基因的診斷率-----------------------------------------------2
1-3 馬凡氏症之臨床病徵-------------------------------------------------------2
1-4 馬凡氏症之診斷方法與臨床運用----------------------------------------2
1-4-1 聚合酶連鎖反應(PCR)之原理-----------------------------------3
1-4-2 DNA片段突變分析儀(DHPLC)之原理-----------------------4
1-4-3 高分辨率熔解曲線 (High Resolution Melting, HRM) 之原理6
1-5 研究動機與方向-------------------------------------------------------------6
二、 實驗材料與儀器--------------------------------------------------7
2-1 實驗材料----------------------------------------------------------------------7
2-1-1 人類基因體DNA(Human Genomic DNA)-----------------7
2-1-2 引子對----------------------------------------------------------------7
2-1-3 聚合酶連鎖反應試劑----------------------------------------------7
2-1-4 跑膠所需的化學藥品----------------------------------------------7
2-1-5 DHPLC所需的化學藥品------------------------------------------8
2-1-6 HRM所需的化學藥品---------------------------------------------9
2-2 實驗儀器----------------------------------------------------------------------9
三、 實驗方法----------------------------------------------------------10
3-1 抽取DNA--------------------------------------------------------------------10
3-2 聚合酶連鎖反應(Polymerase Chain Reaction, PCR)----------------10
3-3 洋菜凝膠電泳(Agarose gel electrophoresis)--------------------------11
3-4 DNA片段突變分析儀(DHPLC)--------------------------------------11
3-5 高分辨率熔解曲線 (High Resolution Melting, HRM)---------------12
3-6 直接定序分析 (Direct DNA sequenceing)-----------------------------12
四、 結果----------------------------------------------------------------14
4-1 聚合酶連鎖反應(Polymerase Chain Reaction, PCR)結果----------14
4-2 DNA片段突變分析儀(DHPLC)結果---------------------------------14
4-3 高分辨率熔解曲線 (High Resolution Melting, HRM) 結果-------14
4-4 資料分析--------------------------------------------------------------------14
五、 討論----------------------------------------------------------------17
5-1 FBN1基因檢測率與文獻之比較----------------------------------------17
5-2 探討馬凡氏症臨床診斷之困難點---------------------------------------18
5-3 實驗之檢討------------------------------------------------------------------19
5-4 新研究平台之開發---------------------------------------------------------19
六、 結論----------------------------------------------------------------21
七、 參考文獻----------------------------------------------------------23

圖目錄
目次
圖一 Fibrillin-1 gene(FBN1)之作用-----------------------------------------27
圖二 Fibrillin蛋白質控制TGF-β蛋白質之活化作用--------------------28
圖三 DHPLC之原理-----------------------------------------------------------29
圖四 HRM之原理-------------------------------------------------------------30
圖五 HRM之流程-------------------------------------------------------------31
圖六 DHPLC 分析結果之範例----------------------------------------------32
圖七 HRM所分析出來的突變圖形與SNP圖形--------------------------33
圖八 HRM所分析出來的不同點位之突變圖形--------------------------34
圖九 FBN1 基因突變類型分佈表-------------------------------------------35
表目錄
目次
表一 Ghent 臨床診斷準則----------------------------------------------------36
表二 台灣人馬凡氏症臨床診斷準則----------------------------------------37
表三 聚合酶連鎖反應所需之引子對和 DHPLC 之沖提條件---------38
表四 PCR 之所需理想反應試劑條件--------------------------------------44
表五 PCR 之理想反應參數--------------------------------------------------45
表六 DHPLC 各緩衝溶液之組成成分-------------------------------------46
表七 DHPLC 之沖提條件----------------------------------------------------47
表八 有馬凡氏症家族史之個案表-------------------------------------------48
表九 沒有馬凡氏症家族史之個案表----------------------------------------53
表十 FBN1基因的突變點位--------------------------------------------------56
表十一 FBN1基因的多型性點位--------------------------------------------57
表十二 馬凡氏症臨床診斷準則----------------------------------------------58
表十三 馬凡氏症病患接受檢測同意書-------------------------------------60
表十四 馬凡氏症之鑑別診斷-------------------------------------------------64
dc.language.isozh-TW
dc.title使用變性高效能液相層析法(DHPLC)來建立高效率的台灣人馬凡氏症基因突變分析方法以及資料庫zh_TW
dc.titleEstablishing a Highly Efficient Detection System of Genetic Diagnosis and the Practical Database for the Taiwanese Marfan Syndrome by using PCR/DHPLC Assayen
dc.typeThesis
dc.date.schoolyear96-2
dc.description.degree碩士
dc.contributor.oralexamcommittee楊偉勛,賴凌平,牛道明
dc.subject.keyword馬凡氏症,變性高效能液相層析法,zh_TW
dc.subject.keywordTaiwanese Marfan Syndrome,FBN1,TGFBR2,en
dc.relation.page64
dc.rights.note有償授權
dc.date.accepted2007-12-28
dc.contributor.author-college醫學院zh_TW
dc.contributor.author-dept分子醫學研究所zh_TW
顯示於系所單位:分子醫學研究所

文件中的檔案:
檔案 大小格式 
ntu-96-1.pdf
  目前未授權公開取用
1.09 MBAdobe PDF
顯示文件簡單紀錄


系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved